Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Scott Small

Interventional Pain Medicine Irvine, CA Doctor of Osteopathy

NPI 1700047669 CMS profile 1037994

35 Creek Rd, Irvine, CA 92604

Open in the dashboard

General payments

$7,924

174 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Scott Small of Irvine, CA is reported in the CMS Open Payments database as having received $7,924 across 174 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 68th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $630 22
2024 General $1,570 34
2023 General $1,789 38
2022 General $2,254 43
2021 General $291 10
2020 General $330 8
2019 General $1,061 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Scott Small
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Scott Small were reported at $630. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Scott Small Interventional Pain Medicine median Middle half National median
2019 $1,061 $684 $216–$2,079 $163
2020 $330 $382 $122–$1,109 $114
2021 $291 $552 $167–$1,554 $132
2022 $2,254 $605 $187–$1,924 $149
2023 $1,789 $671 $195–$1,915 $160
2024 $1,570 $684 $206–$1,837 $164
2025 $630 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $3,005 65 payments
  2. Spinal Simplicity, LLC $1,454 24 payments
  3. Relievant Medsystems, Inc. $1,078 15 payments
  4. Nevro Corp. $414 9 payments
  5. MML US, Inc. $341 1 payment
  6. Electronic Waveform Lab, Inc. $339 33 payments
  7. Stimwave Technologies Incorporated $284 2 payments
  8. Boston Scientific Corporation $284 7 payments
  9. Medtronic USA, Inc. $244 2 payments
  10. Foundation Fusion Solutions, LLC $107 2 payments
  11. Other $375 14 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,629 163 payments
  2. Travel and Lodging $1,296 11 payments
Products named General payments · program years 2019–2025
  1. HA MINUTEMAN G3-R $1,454 24 payments
  2. Intracept Pain $1,078 15 payments
  3. Intracept Pain $1,078 15 payments
  4. Intracept Pain $1,078 15 payments
  5. Intracept Pain $1,078 15 payments
  6. PROCLAIM Neuromodulation $983 17 payments
  7. ETERNA $400 9 payments
  8. PROCLAIM Neuromodulation $366 8 payments
  9. Senza Spinal Cord Stimulation System $358 7 payments
  10. ReActiv8 $341 1 payment
  11. Other $2,163 52 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

603

Median for Interventional Pain Management: 1,220

Drug cost

$9,303

Median for Interventional Pain Management: $39,344

Branded share of claims

26.7%

Median for Interventional Pain Management: 34.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 143 $1,826
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 101 $1,794
Ascomp With Codeine Codeine/Butalbital/Asa/Caffein Brand 11 $1,353
Diclofenac Sodium Generic 32 $847
Celecoxib Generic 29 $780
Omeprazole Generic 48 $518
Morphine Sulfate Er Morphine Sulfate Brand 13 $497
Tizanidine Hcl Generic 30 $338
Ibuprofen Generic 34 $310
Methocarbamol Generic 15 $263

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.

Records

174 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record